Metacrine, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | −$61.1M | −$36.7M | −$30.0M |
| Net income | −$62.2M | −$37.3M | −$28.9M |
| Total assets | $80.0M | $104.2M | $60.3M |
| Total liabilities | — | — | — |
| Equity | $57.4M | $89.3M | −$78.2M |
| EPS (diluted) | — | — | — |
| Shares out. | 26.0M | 26.0M | 2.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- —
- Net margin
- —
- Return on equity
- −108.5%
- Return on assets
- −77.8%
- Return on capital (ROCE)
- −84.6%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $2.21
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Accruals / assets
- −18.8%clean
- Piotroski F-Score
- 1/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 1 good- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Modified shareholder rights · Director / officer change · Shareholder voteMar 24, 2023
- Director / officer changeMar 23, 2023
- Entered a material agreement · Completed an acquisition or dispositionMar 15, 2023
- Delisting / listing-standard noticeMar 3, 2023
- Entered a material agreement · Debt acceleration / triggering eventFeb 9, 2023
- Director / officer changeFeb 3, 2023
- Delisting / listing-standard noticeFeb 1, 2023
- Director / officer change · Other material eventJan 24, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GMar 24, 2023
- 8-KMar 24, 2023
- 4FORM 4 SUBMISSIONMar 24, 2023
- S-8 POSMar 23, 2023
- S-8 POSMar 23, 2023
- 8-KMar 23, 2023
- 8-KMar 15, 2023
- EFFECTMar 7, 2023
- POS AMMar 3, 2023
- 8-KMar 3, 2023
- 25-NSEMar 3, 2023
- SC 13G/AAMENDMENT NO. 1Feb 14, 2023
- DEF 14AFeb 13, 2023
- 8-KFeb 9, 2023
- SC 13G/ANONEFeb 8, 2023